Stage-Setting For Circ Split: Generic Drug Preemption?
Two separate United States Courts of Appeal recently rejected arguments by generic drug manufacturers that they should be treated differently from name-brand manufacturers under the Food, Drug and Cosmetic Act by...To view the full article, register now.
Already a subscriber? Click here to view full article